Jean-Marc Classe, MD, PhD, Institut de Cancèrologie de Lorraine, Vandœuvre-lès-Nancy, France, discusses the Phase III randomized, prospective CARACO trial (NCT01218490) investigating the benefit of performing lymphadenectomies in patients with advanced ovarian cancer. Patients can undergo either primary surgery followed by neoadjuvant chemotherapy or the reverse sequence. The trial focused on detecting an increase in progression-free survival (PFS) without suspicious nodes before treatment, but the results were negative, indicating no benefit. Similarly, the LION trial (NCT00712218), which focused on primary surgery, also found no benefit in performing lymphadenectomies. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
